In both ovarian and breast cancer PARP inhibitor-resistant xenograft models, mice treated with the combination of PARP and ALK inhibitors demonstrated improved survival compared with mice treated with monotherapy (Fig. 6a–d, right panels). The gene discussed is PARP1; the disease is breast carcinoma.